Inhibiting enzyme could provide strategy to halt glioblastoma growth 15 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells in pre-clinical studies.
Synthetic peptides block atherosclerosis in pre-clinical studies 15 February 2021 | By Victoria Rees (Drug Target Review) Researchers have synthesised peptides that function like a soluble chemokine receptor, blocking atherosclerosis in animal models.
Role of enzyme in reactivating neural stem cells in models identified 12 February 2021 | By Victoria Rees (Drug Target Review) An enzyme in fruit fly larvae plays a role in reactivating neural stem cells, which could explain how some neurodevelopmental disorders occur.
Protein sequences provide insight to SARS-CoV-2 infection, study shows 12 February 2021 | By Victoria Rees (Drug Target Review) Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
STING activation reduces graft-versus-host disease in mouse model 12 February 2021 | By Victoria Rees (Drug Target Review) A team has shown that STING activation is a new molecular target in the fight against graft-versus-host disease (GVHD).
Machine learning used to generate AAV capsids for gene therapy 12 February 2021 | By Victoria Rees (Drug Target Review) A study has used artificial intelligence to reveal adeno-associated virus (AAV) capsid variants for use in gene therapies.
CNS target could lead to development of drugs for diabetes 11 February 2021 | By Victoria Rees (Drug Target Review) Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
Scientists reveal four discoveries about early SARS-CoV-2 infection 11 February 2021 | By Victoria Rees (Drug Target Review) Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
Researchers discover factor that triggers muscle stem cells to heal 11 February 2021 | By Victoria Rees (Drug Target Review) In a zebrafish model, researchers have found that the protein NAPMT can trigger muscle stem cells to proliferate and heal muscle damage.
CRISPR used to model acute myeloid leukaemia progression 11 February 2021 | By Victoria Rees (Drug Target Review) CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
ES17 phages can destroy bacteria before gut infection in mice 10 February 2021 | By Victoria Rees (Drug Target Review) A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
ProAgio drug shows success against solid tumours in mice 10 February 2021 | By Victoria Rees (Drug Target Review) Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
EIDD-2801 proven to prevent SARS-CoV-2 infection in vivo 10 February 2021 | By Victoria Rees (Drug Target Review) The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
New small molecules can prevent filovirus infection in cells 9 February 2021 | By Victoria Rees (Drug Target Review) Through a series of experiments, researchers have identified small drug molecules that can inhibit filoviruses such as Ebola and Marburg.
Novel immunotherapy could be effective in patients with HIV 9 February 2021 | By Victoria Rees (Drug Target Review) A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
